Annis Gardner Whiting Capital Advisors LLC Raises Position in Moderna, Inc. (NASDAQ:MRNA)

Annis Gardner Whiting Capital Advisors LLC raised its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 15.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,441 shares of the company’s stock after buying an additional 725 shares during the period. Annis Gardner Whiting Capital Advisors LLC’s holdings in Moderna were worth $226,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB raised its holdings in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after buying an additional 587 shares during the last quarter. Compass Planning Associates Inc purchased a new position in shares of Moderna in the fourth quarter valued at about $37,000. Venturi Wealth Management LLC raised its stake in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after acquiring an additional 664 shares during the last quarter. Crowley Wealth Management Inc. purchased a new stake in shares of Moderna during the fourth quarter worth about $41,000. Finally, MassMutual Private Wealth & Trust FSB grew its stake in shares of Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Price Performance

MRNA stock opened at $25.11 on Friday. Moderna, Inc. has a 1-year low of $23.76 and a 1-year high of $170.47. The stock has a market capitalization of $9.71 billion, a P/E ratio of -2.71 and a beta of 2.23. The business has a fifty day moving average price of $33.55 and a 200-day moving average price of $43.01.

Analyst Upgrades and Downgrades

Several research firms have weighed in on MRNA. Evercore ISI set a $50.00 price objective on Moderna in a report on Friday, February 14th. Argus lowered Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. UBS Group reduced their price objective on shares of Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, February 19th. Morgan Stanley dropped their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 15th. Finally, Leerink Partners reduced their price target on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research report on Thursday, January 16th. Four equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $59.00.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.